Coverage
-
August 24, 2011
UCB Pharma SA and Par Pharmaceutical Inc. on Monday settled a suit Par had filed in Pennsylvania seeking a court declaration that two UCB patents were invalid and not infringed by Par's proposed generic version of the epilepsy drug Keppra.
1 other articles on this case.
View all »